ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 682,34
-0,54%
Dow Jones
40 211,72
0,53%
DAX
18 590,89
-0,95%
Brent Oil
84,105
-0,28%
Bitcoin
64 858,21
0,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
24/02/202402h15GlobeNewswire Inc.Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202402h15Business WireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/202414h30Business WireTeva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/202415h05IH Market NewsHotter-Than-Expected Inflation Data Likely To Weigh On Wall StreetNYSE:TEVATeva Pharmaceutical Industries Ltd
12/02/202423h03IH Market NewsDow Reaches New Record Closing High But Nasdaq, S&P 500 Give Back GroundNYSE:TEVATeva Pharmaceutical Industries Ltd
12/02/202415h13IH Market NewsTeva Pharmaceutical, Urban Outfitters UpgradedNYSE:TEVATeva Pharmaceutical Industries Ltd
01/02/202413h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202413h00Business WireTeva Reports Growth in Fourth Quarter and Full Year 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202412h00Business WireTeva Announces Intention to Divest API Business as Part of Pivot to Growth StrategyNYSE:TEVATeva Pharmaceutical Industries Ltd
02/01/202422h30Business WireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
02/01/202414h50Dow Jones NewsCorcept Therapeutics Shares Slide Premarket on Loss in Teva Patent SuitNYSE:TEVATeva Pharmaceutical Industries Ltd
28/12/202322h30Business WireTeva to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
14/12/202314h30Business WireTeva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and AsthmaNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202317h19Business WireNeue Post-Hoc-Analyse von Phase-3-Daten zeigt, dass AJOVY® (Fremanezumab) Migräneattacken bei Erwachsenen mit Migräne und komorbider Adipositas reduziertNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202315h24Business WireUne nouvelle analyse post hoc des données de phase 3 montre qu’AJOVY® (fremanezumab) réduit les crises de migraine chez les adultes souffrant de migraine et d’obésité comorbideNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202308h00Business WireNew Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid ObesityNYSE:TEVATeva Pharmaceutical Industries Ltd
30/11/202315h23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
30/11/202314h30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
22/11/202313h17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
20/11/202322h30Business WireTeva to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
17/11/202314h30Business WireTeva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
13/11/202314h10GlobeNewswire Inc.Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
13/11/202314h00Business WireTeva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202313h00Business WireTeva Reports Third Quarter 2023 Financial Results and Increases Revenue GuidanceNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202322h30Business WireTeva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients BusinessNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202313h00Business WireTeva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202300h31Business WireUZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet PsychiatryNYSE:TEVATeva Pharmaceutical Industries Ltd
25/10/202315h00Business WireTeva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
17/10/202317h51Business WireL’étude de phase IV UNITE de Teva montre qu’AJOVY® (fremanezumab) réduit les crises de migraine et les symptômes de dépression chez les personnes migraineuses souffrant d’un trouble dépressif majeurNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
AI
Air Liquide
EU
PX4
SBF 120
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
EU
PX1
CAC 40
COIN
BTCUSD
Bitcoin
NYSE
JPM
JP Morgan Chase
EU
VK
Vallourec
EU
RI
Pernod Ricard
EU
LR
Legrand
SPI
SP500
S&P 500
EU
BNP
BNP Paribas
NYSE
NKE
Nike
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés